Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M312Revenue $M6.1Net Margin (%)-1,970.7Z-Score19.8
Enterprise Value $M227EPS $-1.0Operating Margin %-1,992.9F-Score3
P/E(ttm))0Cash Flow Per Share $-0.9Pre-tax Margin (%)-1,970.7Higher ROA y-yY
Price/Book2.610-y EBITDA Growth Rate %0Quick Ratio10.6Cash flow > EarningsY
Price/Sales3605-y EBITDA Growth Rate %13.2Current Ratio10.6Lower Leverage y-yY
Price/Cash Flow0y-y EBITDA Growth Rate %0ROA % (ttm)-30.8Higher Current Ratio y-yN
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)-32.5Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M43.3ROI % (ttm)-27.5Gross Margin Increase y-yN

Gurus Latest Trades with CCXI

Number of guru portfolios checked: 84. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found!

CCXI is held by these Gurus:

Premium Most recent portfolio changes are included for Premium Members only!


CCXI: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Duliege Anne-MarieEVP, Chief of Strategic Dev. 2014-11-18Sell4,970$4.7152.87view
Schall Thomas J.President and CEO 2014-05-01Sell27,726$5.5928.8view
Schall Thomas J.President and CEO 2014-04-29Sell32,274$5.3833.83view
Cappel Markus J.Chief Bus. Officer & Treasurer 2014-04-22Sell20,962$8.17-11.87view
Schall Thomas J.President and CEO 2014-03-17Sell20,000$7.25-0.69view
Schall Thomas J.President and CEO 2014-02-18Sell20,000$7.052.13view
Parker Geoffrey M.Director 2013-12-06Buy20,000$5.1539.81view
BVF PARTNERS L P/IL10% Owner 2013-12-05Buy189,800$5.0143.71view
BVF PARTNERS L P/IL10% Owner 2013-11-06Buy136,066$4.9246.34view
BVF PARTNERS L P/IL10% Owner 2013-11-01Buy336,225$4.9944.29view

Press Releases about CCXI :

    Quarterly/Annual Reports about CCXI:

    News about CCXI:

    Articles On GuruFocus.com
    Three Attractively Priced Small Cap Biotech Stocks Nov 05 2014 
    New ipo recommended Sep 16 2012 


    More From Other Websites
    Can The Uptrend Continue for ChemoCentryx (CCXI)? Dec 15 2014
    ChemoCentryx (CCXI) Shows Strength: Stock Moves Up 24.7% Dec 15 2014
    US STOCKS-Oil slump leads Wall St to worst week in 2-1/2 years Dec 12 2014
    The rout was on, as major averages post worst weekly loss since 2012 Dec 12 2014
    US STOCKS-Oil, materials lead Wall St towards weekly loss Dec 12 2014
    US STOCKS-Oil, materials lead Wall St towards weekly loss Dec 12 2014
    US STOCKS-Wall St declines as oil tumbles further Dec 12 2014
    ChemoCentryx Inc Conference Call to Discuss Top-Line Phase II Results in Patients With Diabetic... Dec 12 2014
    ChemoCentryx Announces Positive Results in Phase II Diabetic Nephropathy Trial With CCR2 Inhibitor... Dec 12 2014
    ChemoCentryx Announces Positive Results in Phase II Diabetic Nephropathy Trial With CCR2 Inhibitor... Dec 12 2014
    ChemoCentryx to Host Conference Call on Friday, December 12, 2014 to Discuss Top-Line Phase II... Dec 11 2014
    ChemoCentryx to Host Conference Call on Friday, December 12, 2014 to Discuss Top-Line Phase II... Dec 11 2014
    ChemoCentryx (CCXI) Shows Strength: Stock Moves Up 5.6% Dec 08 2014
    ChemoCentryx Granted EU Orphan Drug Designation for CCX168, an Orally Administered Complement C5a... Dec 04 2014
    ChemoCentryx's CCX168, an Orally Administered Complement C5a Receptor Inhibitor, Granted Orphan-Drug... Nov 20 2014
    CHEMOCENTRYX, INC. Financials Nov 18 2014
    ChemoCentryx's Orally Administered C5aR Inhibitor CCX168 Shows Benefit in Non-Renal ANCA Vasculitis... Nov 17 2014
    ChemoCentryx's Orally Administered C5aR Inhibitor CCX168 Shows Benefit in Non-Renal ANCA Vasculitis... Nov 17 2014
    CHEMOCENTRYX, INC. Files SEC form 10-Q, Quarterly Report Nov 06 2014
    ChemoCentryx to Present at Two Upcoming Investor Conferences Nov 06 2014

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK